Skip to main content

CCTG Connection



Published:
Category: Trials
Trial Activation: MCY2
The CCTG MYC2 study: Phase III Study of SC Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study S1803)” has been centrally activated.
 
Daratumumab is an anti CD38 monoclonal antibody which is commonly used to treat multiple myeloma.
Read More



Published:
Category:
Canadian Cancer Trials Group

The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.

Read More

Published:
Category: Group updates
CCTG Spring Meeting 2022 - updates
The draft Schedule of Events and meeting policies, including the Invitation Policy and Registration Policy are available on the 2022 Spring Meeting web page. Please check the schedule of events periodically for any meeting changes or additions.
 
If you received an invitation and have not registered please do so now.  If you are unable to attend, we would be grateful if you could please decline your e-invitation.
Read More

Published:
Category: Group updates
Infographics en français!

Now available, CCTG clinical trial Infographics en français!

A great resource for clinical staff and investigators to help patients or even students gain a basic understanding of some of the more complex details of clinical trial research. If you have any questions or would like your site logo added to any of our infographics please contact Lisa Callahan.

You can access our CCTG Infographics in both Francais and English here.

Read More

Published:
Category: News
Dr Joseph Pater

The book “Clinical Trials” by Daniel Schwartz, Robert Flamant and Joseph Lellouch, which described in full detail their distinction between pragmatic and explanatory clinical trials, was published in English in 1980, the year I became the NCIC CTG (now CCTG) director. Their ideas strongly influenced me and my colleagues thinking about how our trials should be designed and conducted.

Read More

Published:
Category: News
The Innovative Cancer Treatments of Tomorrow are Born Through Collaboration
​Annette Hay, Senior Investigator and Co-PI of ExCELLirate Canada, the CCTG-co-Led national platform for exploring the promising applications of cell therapy research across a wide variety of cancers and other illnesses was recently featured as a signature initiative at Queen’s University. Read More



Published:
Category: Group updates

MA36 OlympiA trial: Olaparib (Lynparza) as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

Breast International Group (BIG) has announced that the second interim analysis of OlympiA trial building on the earlier published results (NEJM) will lead to fewer deaths among patients with germline BRCA-mutated (gBRCA) breast cancer, as the U.S. Food and Drug Administration announced last Friday approval of olaparib for gBRCA breast cancer patients who have had chemotherapy.

Read More

Published:
Category: News
Imagine a world where a patient’s own cells are used to cure their cancer. Together, we can do this.
Read More